Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 19/20 | 0.74 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.64 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16518793 | 0.91 | FOLH1 (0.70) | FOLH1RIMKLANAALAD2 | |
| SCHEMBL21344719 | 0.90 | FOLH1 (0.72) | FOLH1RIMKLANAALAD2 | |
| SCHEMBL30608465 | 0.89 | FOLH1 (0.67) | FOLH1RIMKLANAALAD2 | |
| SCHEMBL13674388 | 0.89 | GNPAT (0.64) | FOLH1 | |
| SCHEMBL20341474 | 0.88 | FOLH1 (0.70) | FOLH1RIMKLANAALAD2 | |
| SCHEMBL21337022 | 0.88 | FOLH1 (0.74) | FOLH1RIMKLANAALAD2 | |
| SCHEMBL19840647 | 0.88 | FOLH1 (0.74) | FOLH1RIMKLANAALAD2 | |
| SCHEMBL17119755 | 0.88 | FOLH1 (0.74) | FOLH1RIMKLANAALAD2 | |
| SCHEMBL15860361 | 0.88 | FOLH1 (0.70) | FOLH1RIMKLANAALAD2 | |
| SCHEMBL14729288 | 0.88 | FOLH1 (0.70) | FOLH1RIMKLANAALAD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170081298-A1 | METAL/RADIOMETAL-LABELED PSMA INHIBITORS FOR PSMA-TARGETED IMAGING AND RADIOTHERAPY | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-03-23 | — | — | US | disclosed |
| US-20170081298-A1 | METAL/RADIOMETAL-LABELED PSMA INHIBITORS FOR PSMA-TARGETED IMAGING AND RADIOTHERAPY | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170081298-A1 | METAL/RADIOMETAL-LABELED PSMA INHIBITORS FOR PSMA-TARGETED IMAGING AND RADIOTHERAPY | PSMA6, PSMA1, UTS2R | FOLH1 32/4885RIMKLA 1680/4885NAALAD2 720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.